https://orcid.org/0000-0002-3575-0421
Figures & data
Figure 1. Planning CT scans of solitary lung tumour (upper panel) and lymph node target (lower panel). the GTVs are delineated in red.
Table 1. Patient and tumour characteristics.
Figure 2. Left: Loco-regional recurrence occurred in 16 out of 49 patients resulting in a 1-, 2- and 3-year loco-regional control rate of 77% (SE: 6), 66% (SE: 7), and 64% (SE: 8). in the Middle: the median DFS was 27 months. 1-, 2-, 3-, and 5-year DSF was 65% (SE:7), 51% (SE:7), 49% (SE:7), and 44% (SE:7). right: the median OS was 51 months. 1-, 2-, 3-, and 5-year overall survival was 88% (SE:5), 70% (SE:7), 59% (SE:7), and 50% (SE:8).
Figure 3. At top the DFS related to stage. The median DFS for stage I-II was 79.0 months, for stage III 19.0 months and for stage IV 3.0 months (p = 0.003). At bottom OS for patients with stage I-II, stage III and stage IV. The median OS for stage I-II was 69.0 months, for stage III 96.0 months and stage IV 9.0 months (p = 0.001).
Figure 4. The OS for patients with lymph node targets (green) or primary tumour (blue). the median OS for patients with solitary lymph nodes was 81.0 months and for patients with primary tumours it was 36.0 months (p = 0.069).
Table 2. Early (within 6 months from start of RT) and late toxicity (after 6 months from start of RT).
Supplemental Material
Download MS Word (17.6 KB)Data availability statement
The data that support the findings of this study is available upon reasonable request from the corresponding author (MMK). The data are not publicly available as they contain information that could compromise the privacy of research participations.